Second, outcomes from the BEYOND study match data generated in other randomized, placebo-controlled trials of IFNB: no significant difference in the occurrence of patient-reported depression was found between IFNB-1b and placebo in the original IFNB-1b trial [30]. The gene discussed is IFNB1; the disease is depressive symptom measurement.